

DAFTAR PUSTAKA

1. Vodovotz Y, Billiar TR. In silico modeling: methods and applications to trauma and sepsis. *Crit Care Med.* 2013;41(8):2008-2014.
2. Tsertsvadze A, Royle P, McCarthy N. Community-onset sepsis and its public health burden: protocol of a systematic review. *Syst Rev.* 2015;4(1):119.
3. Zheng G, Lyu J, Huang J, Xiang D, Xie M, Zeng Q. Experimental treatments for mitochondrial dysfunction in sepsis: A narrative review. *J Res Med Sci.* 2015;20(2):185-195.
<http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=4400716&tool=pmcentrez&rendertype=abstract>. Accessed November 17, 2015.
4. Indonesian Research Partnership on Infectious Disease (INA-RESPOND) Pusat Teknologi Terapan Kesehatan Epidemiologi Klinis.
http://www.pusat2.litbang.depkes.go.id/pusat2_v1/supervisi-kabandan-ke-site-ina-respond/. Accessed November 17, 2015.
5. “Early goal-directed therapy” versus “Early” and “goal-directed” therapy for severe sepsis and septic shock: Time to rationalize - ProQuest.
6. Miglietta F, Faneschi ML, Lobreglio G, et al. Procalcitonin, C-reactive protein and serum lactate dehydrogenase in the diagnosis of bacterial sepsis, SIRS and systemic candidiasis. *Infez Med.* 2015;23(3):230-237.
<http://www.ncbi.nlm.nih.gov/pubmed/26397291>. Accessed November 3, 2015.

7. Kurdi MS, Patel T. The role of melatonin in anaesthesia and critical care. *Indian J Anaesth.* 2013;57(2):137-144.
8. Dong W, Mei Q, Yu J, Xu J, Xiang L, Xu Y. Effects of melatonin on the expression of iNOS and COX-2 in rat models of colitis. 2003;9(6):1307-1311.
9. Sener G, Toklu H, Kapucu C, et al. Melatonin protects against oxidative organ injury in a rat model of sepsis. *Surg Today.* 2005;35(1):52-59.
10. Escames G, León J, Macías M, Khaldy H, Acuña-Castroviejo D. Melatonin counteracts lipopolysaccharide-induced expression and activity of mitochondrial nitric oxide synthase in rats. *FASEB J.* 2003;17(8):932-934.
11. Yavuz T, Kaya D, Behcet M, Ozturk E, Yavuz O. Effects of melatonin on Candida sepsis in an experimental rat model. *Adv Ther.* 2007;24(1):91-100.
12. Ayala A, Biron B, Lomas-Neira J. Biomarkers for Sepsis: What Is and What Might Be? *Biomark Insights.* 2015;10(Suppl 4):7.
13. McLean B. Fundamental Critical Care Support. In: *Fourth Edition.* Society of Critical Care Medicine; 2007:11-12.
14. Reactivation of Multiple Viruses in Patients with Sepsis: e98819 - ProQuest. <http://search.proquest.com/docview/1535002745/fulltextPDF/FCEBB62EF2384CD1PQ/8?accountid=49069>. Accessed December 1, 2015.
15. Skrupky LP, Kerby PW, Hotchkiss RS. Advances in the management of sepsis and the understanding of key immunologic defects. *Anesthesiology.* 2011;115(6):1349-1362.

16. Lowes DA, Almawash AM, Webster NR, Reid VL, Galley HF. Melatonin and structurally similar compounds have differing effects on inflammation and mitochondrial function in endothelial cells under conditions mimicking sepsis. *Br J Anaesth*. 2011;107(2):193-201.
17. Marik E. Surviving sepsis going beyond the guidelines. 2011;1:17.
18. Guntur A H. Sepsis. Dalam : Buku Ajar Ilmu Penyakit Dalam. In: *Jakarta. Pusat Penerbitan Ilmu Penyakit Dalam FK UI*. ; 2007:1862-1865.
19. Lai C-C, Shi Z-Y, Chen Y-H, Wang F-D. Effects of various antimicrobial stewardship programs on antimicrobial usage and resistance among common gram-negative bacilli causing healthcare-associated infections: a multicenter comparison. *J Microbiol Immunol Infect*. June 2015.
20. Martin GS, Mannino DM, Eaton S, Moss M. The epidemiology of sepsis in the United States from 1979 through 2000. *N Engl J Med*. 2003;348(16):1546-1554.
21. Zheng D, Yu Y, Li M, et al. Inhibition of miR-195 prevents apoptosis and multiple-organ injury in mouse models of sepsis. *J Infect Dis*. December 2015.
22. Rezaeinasab M, Rad M. Analytical survey of human rabies and animal bite prevalence during one decade in the province of Kerman, Iran. *Crit Care*. 2008;12(Suppl 2):P1.
23. JM S. Sepsis: Definitions, Epidemiology, Etiology and Pathogenesis | The American College of Chest Physicians. sept.




- <http://69.36.35.38/accp/pccsu/sepsis-definitions-epidemiology-etiology-and-pathogenesis?page=0,3>. Published 2009. Accessed January 15, 2016.
24. Steven P. LaRosa M. Cleveland Clinic disease management project: Sepsis. August.
<http://www.clevelandclinicmeded.com/medicalpubs/diseasemanagement/infectious-disease/sepsis/>. Published 2010. Accessed January 14, 2016.
 25. Azkárate I, Choperena G, Salas E, et al. Epidemiology and prognostic factors in severe sepsis/septic shock. Evolution over six years. *Med Intensiva*. March 2015.
 26. Jacobi J. Pathophysiology of sepsis. *Am J Heal Pharm*. 2002;59(SUPPL. 1):1435-1444.
 27. O'Neill R, Morales J, Jule M. Early goal-directed therapy (EGDT) for severe sepsis/septic shock: which components of treatment are more difficult to implement in a community-based emergency department? *J Emerg Med*. 2012;42(5):503-510.
 28. Abramson N, Melton B RB. Leukocytosis : Basics of Clinical Assessment. *American Family Physician*. 2000;62(9):2053-2060.
 29. Pemberton P, Veenith T, Snelson C, Whitehouse T. Is It Time to Beta Block the Septic Patient? *Biomed Res Int*. 2015;2015:424308.
 30. Abbas AK LA. Basic Immunology: Funtions and Disorders of the Immune System. *Philadelphia: Saunders Elsevier*. 2009.
 31. Abbas AK LA. Basic Immunology. Function and disorders of the immune system. Second edition. *Saunders Elseivier,Philadelphia*. 2004;21-185.

32. Abbas AK LA. Cellular and mollecular immunology. *Elsevier SaundersPhiladelphia*. 2005:523-524.
33. Chabot-Richards DS GT. Leukocytosis. *Int J Lab Hematol*. 2014;36(3):279-288.
34. Dellinger RP, Levy MM, Rhodes A et a. Surviving Sepsis Campaign Guidelines Committee including the Pediatric Subgroup. Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock. *Crit Care Med*. 2012;41(2):580-637.
35. Singh M, Jadhav HR. Melatonin: functions and ligands. *Drug Discov Today*. 2014;19(9):1410-1418.
36. Uzenbaeva LB, Vinogradova IA, Kizhina AG, et al. [The melatonin influences on neutrophils/lymphocytes ratio of mammals blood depends on age of animals]. *Adv Gerontol = Uspekhi Gerontol / Ross Akad Nauk Gerontol Obs*. 2012;25(3):409-414.
<http://www.ncbi.nlm.nih.gov/pubmed/23289215>. Accessed November 28, 2015.
37. Reiter RJ, Paredes SD, Manchester LC, Tan D-X. Reducing oxidative/nitrosative stress: a newly-discovered genre for melatonin. *Crit Rev Biochem Mol Biol*. 2009;44(4):175-200.
38. Srinivasan V, Pandi-Perumal SR, Spence DW, Kato H, Cardinali DP. Melatonin in septic shock: Some recent concepts. *J Crit Care*. 2010;25(4):656.e1-e656.e6.
39. Srinivasan V, Spence DW, Moscovitch A, et al. Malaria: therapeutic

- implications of melatonin. *J Pineal Res.* 2010;48(1):1-8..
40. El-Sokkary GH, Reiter RJ, Abdel-Ghaffar SK. Melatonin supplementation restores cellular proliferation and DNA synthesis in the splenic and thymic lymphocytes of old rats. *Neuro Endocrinol Lett.* 24(3-4):215-223. <http://www.ncbi.nlm.nih.gov/pubmed/14523360>. Accessed December 1, 2015.
 41. Carrillo-Vico A, Lardone PJ, Alvarez-Sánchez N, Rodríguez-Rodríguez A, Guerrero JM. Melatonin: buffering the immune system. *Int J Mol Sci.* 2013;14(4):8638-8683.
 42. Raetz CRH, Whitfield C. Lipopolysaccharide endotoxins. *Annu Rev Biochem.* 2002;71:635-700.
 43. Yavuz T, Kaya D, Behcet M, Ozturk E, Yavuz O. Effects of melatonin on Candida sepsis in an experimental rat model. - PubMed - NCBI. 2015. <http://www.ncbi.nlm.nih.gov/pubmed/?term=effect+of+melatonin+on+candida+sepsis+in+experimental+rat+models>. Published 2015. Accessed November 19, 2015.
 44. Li C-X, Liang D-D, Xie G-H, et al. Altered melatonin secretion and circadian gene expression with increased proinflammatory cytokine expression in early-stage sepsis patients. *Mol Med Rep.* 2013;7(4):1117-1122.
 45. Indonesia JA. *Jurnal Anestesiologi Indonesia.* 2012;IV(November):22-33.
 46. Abbas AK, Lichtman AHH, Pillai S. *Basic Immunology: Functions and Disorders of the Immune System.* Vol 5. Elsevier Health Sciences; 2012.
 47. Sastroasmoro Sudigdo. *Dasar-dasar Metodologi Penelitian Klinis.* In: Ed.5

- ed. Jakarta: Sagung Seto; 2014:511.
48. Pacific WHORO for the W. *Research Guidelines for Evaluating the Safety and Efficacy of Herbal Medicines*. World Health Organization, Regional Office for the Western Pacific; 1993.
<https://books.google.com/books?id=2dB8QgAACAAJ&pgis=1>. Accessed January 14, 2016.
 49. Laurence R. of Drug Activities : MOLECULAR The Mode of Action of Biologically.
 50. Dahlan SM. *Statistik Untuk Kedokteran Dan Kesehatan.5th Ed*. Jakarta: Penerbit Salemba; 2011.
<https://books.google.com/books?id=Abh5OaO3qlMC&pgis=1>. Accessed January 13, 2016.
 51. Wu CC, Chiao CW, Hsiao G, Chen A, Yen MH. Melatonin prevents endotoxin-induced circulatory failure in rats. *J Pineal Res*. 2001;30(3):147-156.
 52. Crespo E, Macías M, Pozo D, et al. Melatonin inhibits expression of the inducible NO synthase II in liver and lung and prevents endotoxemia in lipopolysaccharide-induced multiple organ dysfunction syndrome in rats. *FASEB J*. 1999;13(12):1537-1546.
 53. Lin X-J, Mei G-P, Liu J, et al. Therapeutic effects of melatonin on heatstroke-induced multiple organ dysfunction syndrome in rats. *J Pineal Res*. 2011;50(4):436-444.

Lampiran 1. *Ethical Clearance*

	<p>KOMISI ETIK PENELITIAN KESEHATAN (KEPK) FAKULTAS KEDOKTERAN UNIVERSITAS DIPONEGORO DAN RSUP dr KARIADI SEMARANG Sekretariat : Kantor Dekanat FK Undip Lt.3 Jl. Dr. Soetomo 18. Semarang Telp/Fax. 024-8318350</p>	
<h3>ETHICAL CLEARANCE</h3> <p>No. 276/EC/FK-RSDK/2016</p>		
<p>Komisi Etik Penelitian Kesehatan Fakultas Kedokteran Universitas Diponegoro-RSUP. Dr. Kariadi Semarang, setelah membaca dan menelaah Usulan Penelitian</p>		
Judul	:	Pengaruh Melatonin terhadap jumlah Leukosit pada tikus wistar model sepsis
Peneliti	:	Rizqi Indah Riani
Judul	:	Pengaruh Melatonin terhadap kadar asam laktat pada tikus wistar model sepsis
Peneliti	:	Diana Kumalasari
Pembimbing	:	dr. Satrio Adhi Wicaksono, Sp.An
Penelitian	:	Dilaksanakan di Laboratorium Jurusan Biologi Universitas Negeri Semarang sebagai tempat pemeliharaan dan intervensi terhadap hewan coba, Laboratorium Patologi Klinik RSUP. Dr. Kariadi sebagai tempat pembuatan preparat darah tepi Untuk menghitung jumlah leukosit.
<p>Setuju untuk dilaksanakan, dengan memperhatikan prinsip-prinsip yang dinyatakan dalam Deklarasi Helsinki 1975, yang diamended di Seoul 2008 dan Pedoman Nasional Etik Penelitian Kesehatan (PNEPK) Departemen Kesehatan RI 2011</p>		
<p>Pada laporan akhir peneliti harus melampirkan cara pemeliharaan & dekapitasi hewan coba dan melaporkan ke KEPK bahwa penelitian sudah selesai dilampiri Abstrak Penelitian.</p>		
<p>Semarang, 17 MAR 2016</p> <p>Komisi Etik Penelitian Kesehatan Fakultas Kedokteran Undip-RS. Dr. Kariadi Ketua,</p>  <p>Prof. Dr. dr. Suprihati, M.Sc, Sp.THT-KL(K) NIP. 19500621 197703 2 001</p>		

Lampiran 2. Surat Keterangan Penelitian



KEMENTERIAN RISET, TEKNOLOGI DAN PENDIDIKAN TINGGI
UNIVERSITAS NEGERI SEMARANG
FAKULTAS MATEMATIKA DAN ILMU PENGETAHUAN ALAM
LABORATORIUM JURUSAN BIOLOGI
Gedung D 11 Kampus Sekaran Gunungpati Semarang
Website : <http://biologi.unnes.ac.id>

SURAT KETERANGAN

No. /UN. 37.1.4.5./PT/2016

Yang bertanda tangan di bawah ini, Ketua Jurusan Biologi FMIPA Universitas Negeri Semarang menerangkan bahwa :

Nama : Rizqi Indah Riani
Instansi : Fakultas Kedokteran UNDIP Semarang
NIM : 22010112110040
Judul : Pengaruh Melatonin terhadap Jumlah Leukosit pada Tikus Wistar Model Sepsis

telah melakukan terminasi penelitian di Laboratorium Jurusan Biologi FMIPA Universitas Negeri Semarang pada bulan April 2016

Demikian Surat Keterangan ini kami buat untuk dapat digunakan sebagaimana perfunya.

Semarang, 3 Mei 2016

Kepala Laboratorium

Mengetahui
Ketua Jurusan Biologi FMIPA UNNES

Dr. Endah Peniati, M.Si.
NIP. 496511161991032001

Dr. Ning Setiati, M.Si.
NIP. 195903101987032001

Lampiran 3. Hasil Analisis

Case Processing Summary

Pemberian Melatonin		Cases					
				Missing		Total	
		N	Percent	N	Percent	N	Percent
Jumlah Leukosit	Kontrol	6	100.0%	0	0.0%	6	100.0%
	Perlakuan	6	100.0%	0	0.0%	6	100.0%

Case Summaries


Kelompok		Setelah LPS	Melatonin 1	Melatonin 2
Kontrol	N	6	6	6
	Mean	11.1500	13.2167	14.5000
	Std. Deviation	2.20431	2.44820	2.47710
	Median	10.7500	13.3000	14.3500
	Minimum	8.50	9.30	11.20
	Maximum	14.50	16.30	17.70
Perlakuan	N	6	6	6
	Mean	10.5833	9.7167	10.4167
	Std. Deviation	2.46042	2.04589	2.30253
	Median	10.5500	9.8500	10.3000
	Minimum	7.60	6.60	7.90
	Maximum	13.70	12.40	13.00
Total	N	12	12	12
	Mean	10.8667	11.4667	12.4583
	Std. Deviation	2.24675	2.82274	3.12190
	Median	10.6500	11.6000	12.7000
	Minimum	7.60	6.60	7.90
	Maximum	14.50	16.30	17.70

Tests of Normality


Kelompok		Shapiro-Wilk		
		Statistic	df	Sig.
Setelah LPS	Kontrol	.969	6	.889
	Perlakuan	.942	6	.672
Melatonin 1	Kontrol	.975	6	.926
	Perlakuan	.986	6	.976
Melatonin 2	Kontrol	.970	6	.893
	Perlakuan	.863	6	.199

a. Lilliefors Significance Correction


Setelah LPS



Melatonin 1



Melatonin 2



Kelompok Kontrol

T-Test

Paired Samples Statistics

		Mean	N	Std. Deviation	Std. Error Mean
Pair 1	Setelah LPS	11.1500	6	2.20431	.89991
1	Melatonin 1	13.2167	6	2.44820	.99947
Pair 2	Melatonin 1	13.2167	6	2.44820	.99947
2	Melatonin 2	14.5000	6	2.47710	1.01127
Pair 3	Setelah LPS	11.1500	6	2.20431	.89991
3	Melatonin 2	14.5000	6	2.47710	1.01127

Paired Samples Correlations

		N	Correlation	Sig.
Pair 1	Setelah LPS & Melatonin 1	6	.719	.108
Pair 2	Melatonin 1 & Melatonin 2	6	.977	.001
Pair 3	Setelah LPS & Melatonin 2	6	.669	.146

Paired Samples Test

		Pair 1	Pair 2	Pair 3	
		Setelah LPS - Melatonin 1	Melatonin 1 - Melatonin 2	Setelah LPS - Melatonin 2	
Paired Differences	Mean	-2.06667	-1.28333	-3.35000	
	Std. Deviation	1.75917	.52694	1.92120	
	Std. Error Mean	.71818	.21512	.78433	
	95% Confidence Interval of the Difference	Lower	-3.91280	-1.83632	-5.36617
		Upper	-.22053	-.73034	-1.33383
t		-2.878	-5.966	-4.271	
df		5	5	5	
Sig. (2-tailed)		.035	.002	.008	

Kelompok Perlakuan

T-Test

Paired Samples Statistics

		Mean	N	Std. Deviation	Std. Error Mean
Pair 1	Setelah LPS	10.5833	6	2.46042	1.00446
	Melatonin 1	9.7167	6	2.04589	.83523
Pair 2	Melatonin 1	9.7167	6	2.04589	.83523
	Melatonin 2	10.4167	6	2.30253	.94001
Pair 3	Setelah LPS	10.5833	6	2.46042	1.00446
	Melatonin 2	10.4167	6	2.30253	.94001

Paired Samples Correlations

		N	Correlation	Sig.
Pair 1	Setelah LPS & Melatonin 1	6	.505	.306
Pair 2	Melatonin 1 & Melatonin 2	6	.866	.026
Pair 3	Setelah LPS & Melatonin 2	6	.286	.582

Paired Samples Test

		Pair 1	Pair 2	Pair 3
		Setelah LPS - Melatonin 1	Melatonin 1 - Melatonin 2	Setelah LPS - Melatonin 2
Paired Differences	Mean	.86667	-.70000	.16667
	Std. Deviation	2.26951	1.15412	2.84792
	Std. Error Mean	.92652	.47117	1.16266
	95% Confidence Interval of the Difference	Lower Upper	Lower Upper	Lower Upper
		-1.51504 3.24837	-1.91118 .51118	-2.82205 3.15538
t		.935	-1.486	.143
df		5	5	5
Sig. (2-tailed)		.393	.198	.892

T-Test

Group Statistics

	Kelompok	N	Mean	Std. Deviation	Std. Error Mean
Setelah LPS	Kontrol	6	11.1500	2.20431	.89991
	Perlakuan	6	10.5833	2.46042	1.00446

Independent Samples Test

		Setelah LPS	
		Equal variances assumed	Equal variances not assumed
Levene's Test for Equality of Variances	F	.161	
	Sig.	.697	
t-test for Equality of Means	t	.420	.420
	df	10	9.882
	Sig. (2-tailed)	.683	.683
	Mean Difference	.56667	.56667
	Std. Error Difference	1.34862	1.34862
95% Confidence Interval of the Difference	Lower	-2.43825	-2.44314
	Upper	3.57158	3.57647

T-Test

Group Statistics

	Kelompok	N	Mean	Std. Deviation	Std. Error Mean
Melatonin 1	Kontrol	6	13.2167	2.44820	.99947
	Perlakuan	6	9.7167	2.04589	.83523

Independent Samples Test

		Melatonin 1	
		Equal variances assumed	Equal variances not assumed
Levene's Test for Equality of Variances	F	.110	
	Sig.	.747	
t-test for Equality of Means	t	2.687	2.687
	df	10	9.694
	Sig. (2-tailed)	.023	.023
	Mean Difference	3.50000	3.50000
	Std. Error Difference	1.30252	1.30252
	95% Confidence Interval of the Difference	Lower Upper	.59781 6.40219
			.58535 6.41465

T-Test

Group Statistics

Kelompok		N	Mean	Std. Deviation	Std. Error Mean
Melatonin 2	Kontrol	6	14.5000	2.47710	1.01127
	Perlakuan	6	10.4167	2.30253	.94001

Independent Samples Test

		Melatonin 2	
		Equal variances assumed	Equal variances not assumed
Levene's Test for Equality of Variances	F	.008	
	Sig.	.931	
t-test for Equality of Means	t	2.957	2.957
	df	10	9.947
	Sig. (2-tailed)	.014	.014
	Mean Difference	4.08333	4.08333
	Std. Error Difference	1.38068	1.38068
	95% Confidence Interval of the Difference	Lower Upper	1.00699 7.15968
			1.00477 7.16190

Case Summaries


Kelompok		Selisih Setelah LPS - Melatonin 1	Selisih Setelah LPS - Melatonin 2
Kontrol	N	6	6
	Mean	2.0667	3.3500
	Std. Deviation	1.75917	1.92120
	Median	1.8000	2.6000
	Minimum	.70	2.10
	Maximum	5.50	7.20
Perlakuan	N	6	6
	Mean	-.8667	-.1667
	Std. Deviation	2.26951	2.84792
	Median	-.4000	.6000
	Minimum	-3.70	-4.70
	Maximum	1.30	2.80
Total	N	12	12
	Mean	.6000	1.5917
	Std. Deviation	2.46871	2.95587
	Median	1.0000	2.2500
	Minimum	-3.70	-4.70
	Maximum	5.50	7.20

Tests of Normality


Kelompok		Shapiro-Wilk		
		Statistic	df	Sig.
Selisih Setelah LPS - Melatonin 1	Kontrol	.733	6	.013
	Perlakuan	.844	6	.140
Selisih Setelah LPS - Melatonin 2	Kontrol	.672	6	.003
	Perlakuan	.927	6	.559

a. Lilliefors Significance Correction

Selish Setelah LPS - Melatonin 1



Selish Setelah LPS - Melatonin 2



NPar Tests

Mann-Whitney Test

Ranks

	Kelompok	N	Mean Rank	Sum of Ranks
Selisih Setelah LPS - Melatonin 1	Kontrol	6	8.58	51.50
	Perlakuan	6	4.42	26.50
	Total	12		
Selisih Setelah LPS - Melatonin 2	Kontrol	6	8.83	53.00
	Perlakuan	6	4.17	25.00
	Total	12		

Test Statistics^b

	Selisih Setelah LPS - Melatonin 1	Selisih Setelah LPS - Melatonin 2
Mann-Whitney U	5.500	4.000
Wilcoxon W	26.500	25.000
Z	-2.019	-2.242
Asymp. Sig. (2-tailed)	.043	.025
Exact Sig. [2*(1-tailed Sig.)]	.041 ^a	.026 ^a

a. Not corrected for ties.

b. Grouping Variable: Kelompok

Lampiran 4. Dokumentasi Penelitian



Lampiran 5. Biodata Mahasiswa

Identitas

Nama : Rizqi Indah Riani
NIM : 22010112110040
Tempat/tanggal lahir : Klaten,19 desember 1993
Jenis Kelamin : Perempuan
Alamat : Jl koprak Sayom Gg Sidoasih Sekaranom Klaten Utara
Nomor Telepon : (0272) 326052
Nomor HP : 081377313107
e-mail : riiz_qiindah@yahoo.com

Riwayat Pendidikan Formal

1. SD : SD N 1 Klaten Lulus tahun: 2006
2. SMP : SMP N 2 Klaten Lulus tahun: 2009
3. SMA : SMA N 1 Klaten Lulus tahun: 2012
4. FK UNDIP : Masuk tahun : 2012

Keanggotaan Organisasi

1. Staf Bidang EKUIN HIMA KU Undip Tahun 2012 s/d 2014
2. Staf Bidang Annisa Rohis KU Undip Tahun 2012 s/d 2013